Fixed-ratio combination of GLP-1 receptor agonist and basal insulin: simplifying type 2 diabetes treatment

This publication has 22 references indexed in Scilit:

• Efficacy and safety of iGlarLixi versus insulin glargine in type 2 diabetes: a meta-analysis of randomized controlled trials
  Endocrine, 2025
• Once-weekly IcoSema versus once-weekly semaglutide in adults with type 2 diabetes: the COMBINE 2 randomised clinical trial
  Diabetologia, 2025
• Pharmacokinetic Properties of a Once-Weekly Fixed-Ratio Combination of Insulin Icodec and Semaglutide Compared with Separate Administration of Each Component in Individuals with Type 2 Diabetes Mellitus
  Clinical Drug Investigation, 2024
• Once-weekly insulins: a promising approach to reduce the treatment burden in people with diabetes
  Diabetologia, 2024
• BEYOND 2 years: durability of metabolic benefits by simplification of complex insulin regimens in type 2 diabetes
  Endocrine, 2023
• IDegLira for type 2 diabetes: a systematic review and meta-analysis
  Endocrine, 2023
• Initiation of the Fixed Combination IDegLira in Patients with Type 2 Diabetes on Prior Injectable Therapy: Insights from the EASY French Real-World Study
  Diabetes Therapy, 2022
• Expert Panel Guidance and Narrative Review of Treatment Simplification of Complex Insulin Regimens to Improve Outcomes in Type 2 Diabetes
  Diabetes Therapy, 2022
• Effect of deprescribing in elderly patients with type 2 diabetes: iDegLira might improve quality of life
  Biomedicine & Pharmacotherapy, 2021
• The good companions: insulin and glucagon-like peptide-1 receptor agonist in type 2 diabetes. A systematic review and meta-analysis of randomized controlled trials
  Diabetes Research and Clinical Practice, 2019